Corrigendum to ‘Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study’ [The Lancet Regional Health – Europe 35 (2023) 100747] (The Lancet Regional Health - Europe (2023) 35, (S2666776223001667), (10.1016/j.lanepe.2023.100747))
Journal article
Evans RA. et al, (2024), The Lancet Regional Health - Europe, 44
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Journal article
Lim YJ. et al, (2024), Br J Haematol
Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV.
Journal article
Davis C. et al, (2024), Vaccines (Basel), 12
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Journal article
Goodyear CS. et al, (2024), Lancet Rheumatol
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
Journal article
Jackson S. et al, (2024), Lancet Microbe
Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation.
Journal article
Campbell C. et al, (2024), Public Health, 226, 215 - 227
Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.
Journal article
Murray SM. et al, (2024), J Hepatol, 80, 109 - 123
HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol.
Journal article
Arif A. et al, (2023), BMC Public Health, 23
Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length Genomes.
Journal article
Christensen KT. et al, (2023), Viruses, 15
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.
Journal article
Cargill T. et al, (2023), JHEP Rep, 5
Joint statement in support of hepatitis C human challenge studies.
Journal article
Alter HJ. et al, (2023), Lancet Gastroenterol Hepatol, 8, 967 - 969
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study.
Journal article
Neale I. et al, (2023), mBio, 14
Correction to: Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies.
Journal article
Gillespie IA. et al, (2023), Infect Dis Ther
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history.
Journal article
Hornsby H. et al, (2023), Nat Commun, 14
Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study.
Journal article
Hamill V. et al, (2023), BMJ, 382
Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies.
Journal article
Gillespie IA. et al, (2023), Infect Dis Ther
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
Journal article
Barnes E. et al, (2023), Nat Med, 29, 1760 - 1774
Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.
Journal article
Johnson SA. et al, (2023), Clin Exp Immunol, 212, 249 - 261
An enrichment protocol and analysis pipeline for long read sequencing of the hepatitis B virus transcriptome.
Journal article
Ng E. et al, (2023), J Gen Virol, 104
Disparities in care and outcomes for primary liver cancer in England during 2008-2018: a cohort study of 8.52 million primary care population using the QResearch database.
Journal article
Liao W. et al, (2023), EClinicalMedicine, 59